Stefaan Rossenu

Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs

Hans Ulrichts, Karen Silence, Anne Schoolmeester et al. · Blood · 2011 · 178 citations · Full text

Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura

Filip Callewaert, Jan Roodt, Hans Ulrichts et al. · Blood · 2012 · 140 citations

Using Model-Based “Learn and Confirm” to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial

Jeroen Elassaiss‐Schaap, Stefaan Rossenu, Andreas Lindauer et al. · CPT Pharmacometrics & Systems Pharmacology · 2016 · 112 citations · Full text

Keynote-001 Trial, Confirm ”, Pembrolizumab Pks +21

Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression

Carlos Pérez‐Ruixo, Stefaan Rossenu, Peter Zannikos et al. · Clinical Pharmacokinetics · 2020 · 69 citations

Psychoactive Drug, Healthy Subjects, Psychiatry +11

The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension

Nicolas Darville, Marjolein van Heerden, Dirk Mariën et al. · Journal of Controlled Release · 2016 · 62 citations · Full text

Pharmaceutical Science, Pharmacological Study, Angiogenesis Inhibition +8